ANDA 202033, held by Mylan Pharmaceuticals. Metoprolol Succinate.
As of Nov 19, 2026, ANDA 202033 (Metoprolol Succinate), held by Mylan Pharmaceuticals, was first approved by FDA on Dec 15, 2011, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 15, 2011 | Original application | Approved | None posted |
| Metoprolol SuccinateEQ 25MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Discontinued |
| Metoprolol SuccinateEQ 50MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Discontinued |
| Metoprolol SuccinateEQ 100MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Discontinued |
| Metoprolol SuccinateEQ 200MG TARTRATE ยท tablet, extended release;oral | Metoprolol Succinate | Discontinued |
| Sep 12, 2023 | Supplement 14Labeling ยท Standard review | Approved | None posted |
| Apr 11, 2023 | Supplement 9Labeling ยท Standard review | Approved | None posted |
| Apr 11, 2023 | Supplement 11Labeling ยท Standard review | Approved | None posted |
| Jun 13, 2016 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Dec 15, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters